Catalyst Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CPRX research report →
Companywww.catalystpharma.com
Catalyst Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
- CEO
- Richard John Daly
- IPO
- 2006
- Employees
- 181
- HQ
- Coral Gables, FL, US
Price Chart
Valuation
- Market Cap
- $3.82B
- P/E
- 17.26
- P/S
- 6.41
- P/B
- 3.77
- EV/EBITDA
- 9.79
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 82.32%
- Op Margin
- 44.83%
- Net Margin
- 37.08%
- ROE
- 23.65%
- ROIC
- 19.67%
Growth & Income
- Revenue
- $588.99M · 19.78%
- Net Income
- $214.33M · 30.78%
- EPS
- $1.75 · 26.81%
- Op Income
- $257.78M
- FCF YoY
- -12.81%
Performance & Tape
- 52W High
- $32.56
- 52W Low
- $19.05
- 50D MA
- $26.58
- 200D MA
- $23.29
- Beta
- 0.72
- Avg Volume
- 1.99M
Get TickerSpark's AI analysis on CPRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 17, 26 | Russo Gregg | other | 687 |
| Feb 17, 26 | Russo Gregg | other | 687 |
| Feb 17, 26 | Russo Gregg | other | 211 |
| Jan 5, 26 | Kalb Michael Wayne | other | 7,139 |
| Jan 5, 26 | Kalb Michael Wayne | other | 7,139 |
| Jan 5, 26 | Kalb Michael Wayne | other | 2,080 |
| Jan 5, 26 | Daly Richard J | other | 42,105 |
| Jan 5, 26 | Daly Richard J | other | 42,105 |
| Jan 5, 26 | Daly Richard J | other | 10,577 |
| Dec 29, 25 | DENKHAUS DONALD A | other | 1,334 |
Our CPRX Coverage
We haven't published any research on CPRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CPRX Report →